| A phase 3 randomized trial of voxelotor in sickle cell disease E Vichinsky, CC Hoppe, KI Ataga, RE Ware, V Nduba, A El-Beshlawy, ... New England Journal of Medicine 381 (6), 509-519, 2019 | 575 | 2019 |
| A randomized trial of factor VIII and neutralizing antibodies in hemophilia A F Peyvandi, PM Mannucci, I Garagiola, A El-Beshlawy, M Elalfy, ... New England Journal of Medicine 374 (21), 2054-2064, 2016 | 527 | 2016 |
| Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study AT Taher, KM Musallam, M Karimi, A El-Beshlawy, K Belhoul, S Daar, ... Blood, The Journal of the American Society of Hematology 115 (10), 1886-1892, 2010 | 462 | 2010 |
| Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias MD Cappellini, J Porter, A El-Beshlawy, CK Li, JF Seymour, M Elalfy, ... haematologica 95 (4), 557, 2010 | 346 | 2010 |
| Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia DJ Pennell, JB Porter, MD Cappellini, A El-Beshlawy, LL Chan, Y Aydinok, ... Blood, The Journal of the American Society of Hematology 115 (12), 2364-2371, 2010 | 237 | 2010 |
| Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia: the ESCALATOR study A Taher, A El‐Beshlawy, MS Elalfy, K Al Zir, S Daar, D Habr, ... European journal of haematology 82 (6), 458-465, 2009 | 198 | 2009 |
| Splenectomy and thrombosis: the case of thalassemia intermedia AT Taher, KM Musallam, M Karimi, A El‐Beshlawy, K Belhoul, S Daar, ... Journal of Thrombosis and Haemostasis 8 (10), 2152-2158, 2010 | 175 | 2010 |
| Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry A Tylki‐Szymańska, A Vellodi, A El‐Beshlawy, JA Cole, E Kolodny Journal of Inherited Metabolic Disease: Official Journal of the Society for …, 2010 | 169 | 2010 |
| Age‐related complications in treatment‐naive patients with thalassaemia intermedia AT Taher, KM Musallam, A El‐Beshlawy, M Karimi, S Daar, K Belhoul, ... British journal of haematology 150 (4), 486-489, 2010 | 162 | 2010 |
| Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major DJ Pennell, JB Porter, MD Cappellini, LL Chan, A El-Beshlawy, Y Aydinok, ... haematologica 97 (6), 842, 2012 | 156 | 2012 |
| Revised recommendations for the management of Gaucher disease in children P Kaplan, H Baris, L De Meirleir, M Di Rocco, A El-Beshlawy, M Huemer, ... European journal of pediatrics 172, 447-458, 2013 | 148 | 2013 |
| Multicenter validation of spin‐density projection‐assisted R2‐MRI for the noninvasive measurement of liver iron concentration TG St Pierre, A El‐Beshlawy, M Elalfy, A Al Jefri, K Al Zir, S Daar, D Habr, ... Magnetic resonance in medicine 71 (6), 2215-2223, 2014 | 139 | 2014 |
| A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA) DJ Pennell, JB Porter, A Piga, Y Lai, A El-Beshlawy, KM Belhoul, M Elalfy, ... Blood, The Journal of the American Society of Hematology 123 (10), 1447-1454, 2014 | 136 | 2014 |
| Prevention of hemoglobinopathies in Egypt A El-Beshlawy, I Youssry Hemoglobin 33 (sup1), S14-S20, 2009 | 128 | 2009 |
| Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload DJ Pennell, JB Porter, MD Cappellini, LL Chan, A El-Beshlawy, Y Aydinok, ... haematologica 96 (1), 48, 2011 | 91 | 2011 |
| The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload M El Alfy, TT Sari, CL Lee, F Tricta, A El-Beshlawy Journal of pediatric hematology/oncology 32 (8), 601-605, 2010 | 86 | 2010 |
| Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study Y Aydinok, JB Porter, A Piga, M Elalfy, A El‐Beshlawy, Y Kilinç, ... European journal of haematology 95 (3), 244-253, 2015 | 85 | 2015 |
| Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial J Howard, KI Ataga, RC Brown, M Achebe, V Nduba, A El-Beshlawy, ... The Lancet Haematology 8 (5), e323-e333, 2021 | 84 | 2021 |
| Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload Y Aydinok, A Kattamis, MD Cappellini, A El-Beshlawy, R Origa, M Elalfy, ... Blood, The Journal of the American Society of Hematology 125 (25), 3868-3877, 2015 | 83 | 2015 |
| Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study KM Musallam, MD Cappellini, S Daar, M Karimi, A El-Beshlawy, ... Haematologica 99 (11), e218, 2014 | 82 | 2014 |
